Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact.

Abstact

<b>Aim:</b> p16 and p53 are frequently altered intracellular pathways in cancers. We investigated the aberrant expression of p16 and its relationship with p53 and HPV status in primary non-small-cell lung carcinoma. <b>Patients & methods:</b> Lung tumor tissue microarray (n = 163), immunohistochemical study of p16 and p53, and HPV <i>in-situ</i> hybridization were analyzed. <b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). HPV was detected in 16 and 10.2% of ADC and squamous cell carcinoma. In ADCs, p16 positive tumors demonstrated a favorable median overall survival time of 60.9 months, compared with p16 negative tumors of 46.9 months (p < 0.05). Furthermore, we did not find significant relationships between p16 expression and HPV status, nor with p53 expression. <b>Conclusion:</b> p16 play an unique role in lung cancer survival. The mechanism of p16 needs to be further studied.

Authors
  • Ao M
  • Askin F
  • Gabrielson E
  • Höti N
  • Li L
  • Li QK
  • Zhang H
  • Zhang Z
  • Zhou Y
  • Zhu H
Pub Med ID
Appears In
Biomark Med, 2019, 13 (9)